Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Mar;84(5):587–593. doi: 10.1054/bjoc.2001.1680

Morphine and alternative opioids in cancer pain: the EAPC recommendations

Expert Working Group of the Research Network of the European Association for Palliative Care

G W Hanks 1, F de Conno 2, N Cherny 3, M Hanna 4, E Kalso 5, H J McQuay 6, S Mercadante 7, J Meynadier 8, P Poulain 9, C Ripamonti 2, L Radbruch 10, J Roca i Casas 11, J Sawe 12, R G Twycross 13, V Ventafridda 14
PMCID: PMC2363790  PMID: 11237376

Abstract

An expert working group of the European Association for Palliative Care has revised and updated its guidelines on the use of morphine in the management of cancer pain. The revised recommendations presented here give guidance on the use of morphine and the alternative strong opioid analgesics which have been introduced in many parts of the world in recent years. Practical strategies for dealing with difficult situations are described presenting a consensus view where supporting evidence is lacking. The strength of the evidence on which each recommendation is based is indicated. © 2001 Cancer Research Campaign

Keywords: morphine, alternative opioids, European guidelines

Full Text

The Full Text of this article is available as a PDF (66.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bruera E., Belzile M., Pituskin E., Fainsinger R., Darke A., Harsanyi Z., Babul N., Ford I. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol. 1998 Oct;16(10):3222–3229. doi: 10.1200/JCO.1998.16.10.3222. [DOI] [PubMed] [Google Scholar]
  2. Chrubasik J., Wüst H., Friedrich G., Geller E. Absorption and bioavailability of nebulized morphine. Br J Anaesth. 1988 Aug;61(2):228–230. doi: 10.1093/bja/61.2.228. [DOI] [PubMed] [Google Scholar]
  3. Collins S. L., Faura C. C., Moore R. A., McQuay H. J. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage. 1998 Dec;16(6):388–402. doi: 10.1016/s0885-3924(98)00094-3. [DOI] [PubMed] [Google Scholar]
  4. De Conno F., Groff L., Brunelli C., Zecca E., Ventafridda V., Ripamonti C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol. 1996 Oct;14(10):2836–2842. doi: 10.1200/JCO.1996.14.10.2836. [DOI] [PubMed] [Google Scholar]
  5. Dover S. B. Syringe driver in terminal care. Br Med J (Clin Res Ed) 1987 Feb 28;294(6571):553–555. doi: 10.1136/bmj.294.6571.553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eisenach J. C., DuPen S., Dubois M., Miguel R., Allin D. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain. 1995 Jun;61(3):391–399. doi: 10.1016/0304-3959(94)00209-W. [DOI] [PubMed] [Google Scholar]
  7. Glare P. A., Walsh T. D. Clinical pharmacokinetics of morphine. Ther Drug Monit. 1991 Jan;13(1):1–23. doi: 10.1097/00007691-199101000-00001. [DOI] [PubMed] [Google Scholar]
  8. Gourlay G. K., Cherry D. A., Onley M. M., Tordoff S. G., Conn D. A., Hood G. M., Plummer J. L. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain. 1997 Feb;69(3):295–302. doi: 10.1016/S0304-3959(96)03269-1. [DOI] [PubMed] [Google Scholar]
  9. Hanks G. W., Hoskin P. J., Aherne G. W., Turner P., Poulain P. Explanation for potency of repeated oral doses of morphine? Lancet. 1987 Sep 26;2(8561):723–725. doi: 10.1016/s0140-6736(87)91083-x. [DOI] [PubMed] [Google Scholar]
  10. Hanks G. W. Opioid-responsive and opioid-non-responsive pain in cancer. Br Med Bull. 1991 Jul;47(3):718–731. doi: 10.1093/oxfordjournals.bmb.a072503. [DOI] [PubMed] [Google Scholar]
  11. Hoskin P. J., Hanks G. W., Aherne G. W., Chapman D., Littleton P., Filshie J. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol. 1989 Apr;27(4):499–505. doi: 10.1111/j.1365-2125.1989.tb05399.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jadad A. R., Browman G. P. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA. 1995 Dec 20;274(23):1870–1873. [PubMed] [Google Scholar]
  13. Kaiko R. F. The therapeutic equivalence of i.m. and p.o. administration of morphine--1:3 or 1:6? J Palliat Care. 1988 May;4(1-2):64–66. [PubMed] [Google Scholar]
  14. Kalso E., Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther. 1990 May;47(5):639–646. doi: 10.1038/clpt.1990.85. [DOI] [PubMed] [Google Scholar]
  15. Lehmann K. A., Zech D. Transdermal fentanyl: clinical pharmacology. J Pain Symptom Manage. 1992 Apr;7(3 Suppl):S8–16. doi: 10.1016/0885-3924(92)90048-m. [DOI] [PubMed] [Google Scholar]
  16. McQuay H. Opioids in pain management. Lancet. 1999 Jun 26;353(9171):2229–2232. doi: 10.1016/S0140-6736(99)03528-X. [DOI] [PubMed] [Google Scholar]
  17. Megens A. A., Artois K., Vermeire J., Meert T., Awouters F. H. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage. 1998 Apr;15(4):253–257. doi: 10.1016/s0885-3924(97)00371-0. [DOI] [PubMed] [Google Scholar]
  18. Mercadante S. Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home. Cancer. 1999 Apr 15;85(8):1849–1858. doi: 10.1002/(sici)1097-0142(19990415)85:8<1849::aid-cncr27>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  19. Mercadante S. Problems of long-term spinal opioid treatment in advanced cancer patients. Pain. 1999 Jan;79(1):1–13. doi: 10.1016/S0304-3959(98)00118-3. [DOI] [PubMed] [Google Scholar]
  20. Moulin D. E., Kreeft J. H., Murray-Parsons N., Bouquillon A. I. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet. 1991 Feb 23;337(8739):465–468. doi: 10.1016/0140-6736(91)93401-t. [DOI] [PubMed] [Google Scholar]
  21. Plummer J. L., Gourlay G. K., Cherry D. A., Cousins M. J. Estimation of methadone clearance: application in the management of cancer pain. Pain. 1988 Jun;33(3):313–322. doi: 10.1016/0304-3959(88)90290-4. [DOI] [PubMed] [Google Scholar]
  22. Portenoy R. K., Hagen N. A. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990 Jun;41(3):273–281. doi: 10.1016/0304-3959(90)90004-W. [DOI] [PubMed] [Google Scholar]
  23. Portenoy R. K., Payne R., Coluzzi P., Raschko J. W., Lyss A., Busch M. A., Frigerio V., Ingham J., Loseth D. B., Nordbrock E. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain. 1999 Feb;79(2-3):303–312. doi: 10.1016/s0304-3959(98)00179-1. [DOI] [PubMed] [Google Scholar]
  24. Ripamonti C., Bruera E. Rectal, buccal, and sublingual narcotics for the management of cancer pain. J Palliat Care. 1991 Spring;7(1):30–35. [PubMed] [Google Scholar]
  25. Ripamonti C., Groff L., Brunelli C., Polastri D., Stavrakis A., De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol. 1998 Oct;16(10):3216–3221. doi: 10.1200/JCO.1998.16.10.3216. [DOI] [PubMed] [Google Scholar]
  26. Säwe J., Dahlström B., Rane A. Steady-state kinetics and analgesic effect of oral morphine in cancer patients. Eur J Clin Pharmacol. 1983;24(4):537–542. doi: 10.1007/BF00609900. [DOI] [PubMed] [Google Scholar]
  27. Säwe J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet. 1986 Mar-Apr;11(2):87–106. doi: 10.2165/00003088-198611020-00001. [DOI] [PubMed] [Google Scholar]
  28. Twycross R. G. Control of pain. J R Coll Physicians Lond. 1984 Jan;18(1):32–39. [PMC free article] [PubMed] [Google Scholar]
  29. Twycross R. G. The therapeutic equivalence of oral and subcutaneous/intramuscular morphine sulphate in cancer patients. J Palliat Care. 1988 May;4(1-2):67–68. [PubMed] [Google Scholar]
  30. Vainio A., Ollila J., Matikainen E., Rosenberg P., Kalso E. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet. 1995 Sep 9;346(8976):667–670. doi: 10.1016/s0140-6736(95)92281-4. [DOI] [PubMed] [Google Scholar]
  31. de Stoutz N. D., Bruera E., Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 1995 Jul;10(5):378–384. doi: 10.1016/0885-3924(95)90924-c. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES